Business Wire
24 Oct 2025, 16:30 UTC · 49w ago
Impact · against what's priced in
Xencor's initial Phase 1 data for XmAb819 in ccRCC marks a positive clinical milestone. However, the lack of specific efficacy data in the announcement limits the immediate impact on the stock price.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish
Xencor announced initial results from a Phase 1 dose-escalation study of XmAb819 for advanced clear cell renal cell carcinoma.
More positive than 53% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The announcement of initial results from a Phase 1 dose-escalation study for XmAb819 indicates clinical progress in treating advanced clear cell renal cell carcinoma.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 68% of ticker scores this week
The company announced initial results from a Phase 1 study for its candidate XmAb819, indicating clinical progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
19h ago
+98.6%
Price agrees with the score
$24.50 vs $12.34 close before publication (Oct 23) · not market-adjusted
XNCR chart →
